Posts by: Alice Melão

News

Interim data from an ongoing Phase 1/2 clinical trial show that Celgene’s investigational therapy iberdomide (CC-220), used in combination with dexamethasone, is safe and controlled disease in nearly 90% ... Read more

May 13, 2019May 13, 2019

Phase 3 Trial of Immune System-targeting Treatment for Advanced Multiple Myeloma Begins Dosing

News

A pivotal Phase 3 clinical trial has begun dosing participants to evaluate MorphoSys‘s investigational antibody, MOR202 (TJ202), in combination with Revlimid (lenalidomide) plus dexamethasone, for the treatment of relapsed ... Read more

April 15, 2019

MolMed Receives Green Light for Phase 1/2 Trial to Test CAR T-cell Therapy in Myeloma, Leukemia Patients

News

The Italian Medicines Agency has approved a first-in-human clinical trial testing MolMed’s investigational CAR T-cell product, CD44v6, for the treatment of acute myeloid leukemia and multiple myeloma, the company announced. The ... Read more

March 27, 2019

FDA Puts Partial Hold on Venetoclax’s Multiple Myeloma Trials

News

The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on venetoclax’s multiple myeloma trials after new safety concerns were raised during a review of the ... Read more

March 25, 2019

Phase 1/2 Trial of Tinostamustine Recruiting Patients with Myeloma, Other Blood Cancers

News

The expansion part of a Phase 1/2 clinical trial testing tinostamustine in relapsed or refractory blood cancers has begun treating the first patient. The trial (NCT02576496), conducted by Mundipharma EDO ... Read more

March 4, 2019

Gamida, Editas Partner to Create Genetically Engineered NAM-NK Cells for Treating Blood, Solid Cancers

News

Gamida Cell and Editas Medicine have entered a partnership to explore the potential of using gene-editing technology to enhance the activity of certain immune cells against blood and solid cancers. Under ... Read more

February 20, 2019February 20, 2019

Partners to Develop and Market TNB-383B Antibody for Multiple Myeloma

News

The development and commercialization of TNB-383B — an anti-BCMA antibody for the potential treatment of multiple myeloma — is being advanced as part of a new collaboration between AbbVie, Teneobio, and ... Read more

February 8, 2019

Thalidomide at 100 mg Shows Benefits as Maintenance Therapy in Multiple Myeloma Patients in Trial

News

A maintenance treatment with thalidomide at 100 mg a day was safe and seen to delay disease progression by more than three years in multiple myeloma patients with stable disease in ... Read more

December 10, 2018

AMG 420 Immunotherapy Shows Promise in Relapsed or Refractory Multiple Myeloma

News

Results from the first in-human clinical trial assessing Amgen’s immunotherapy AMG 420 showed promising results in multiple myeloma patients who had received at least two prior lines of therapy. The ... Read more

December 3, 2018

Seattle Genetics Initiates Phase 1 Trial of SEA-BCMA in Relapsed or Refractory Multiple Myeloma Patients

News

Seattle Genetics is recruiting patients with relapsed or refractory multiple myeloma into a Phase 1 clinical trial to study the safety and tolerability of its investigational antibody SEA-BCMA. The ... Read more

Posts by: Alice Melão

Alice Melão

Early Data Show Positive Activity of Iberdomide Against Heavily Treated MM

Phase 3 Trial of Immune System-targeting Treatment for Advanced Multiple Myeloma Begins Dosing

MolMed Receives Green Light for Phase 1/2 Trial to Test CAR T-cell Therapy in Myeloma, Leukemia Patients

FDA Puts Partial Hold on Venetoclax’s Multiple Myeloma Trials

Phase 1/2 Trial of Tinostamustine Recruiting Patients with Myeloma, Other Blood Cancers

Gamida, Editas Partner to Create Genetically Engineered NAM-NK Cells for Treating Blood, Solid Cancers

Partners to Develop and Market TNB-383B Antibody for Multiple Myeloma

Thalidomide at 100 mg Shows Benefits as Maintenance Therapy in Multiple Myeloma Patients in Trial

AMG 420 Immunotherapy Shows Promise in Relapsed or Refractory Multiple Myeloma

Seattle Genetics Initiates Phase 1 Trial of SEA-BCMA in Relapsed or Refractory Multiple Myeloma Patients

Pin It on Pinterest